Development status: Approved, off-patent

Combination therapy

Mechanism of Action/Target pathogen: Inhibits monoamine oxidase activity. Active against many Enterobacteriaceae (Salmonella, shigella) and Helicobacter pylori.

Additional information: Synthetic compound. Oral application for eradication of Helicobacter pylori. Used in veterinary medicine